Precision Biosciences Profit Margin

Precision Biosciences (DTIL) currently reports a profit margin of -117.04% as of June 2026. That compares with -6205.79% in the prior-year period — up 98.1% year over year. That is below the Healthcare sector average of 14.34%. Use the charts on this page to explore Precision Biosciences's profit margin history and peer comparisons.

Precision Biosciences's profit margin increased from -6205.79% to -117.04% — a 98.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Precision Biosciences's profit margin of -117.04% is lower than the Healthcare sector average of 14.34%. That is roughly 915.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Precision Biosciences's current -117.04% should be judged against Healthcare norms (sector average: 14.34%) and against DTIL's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -117.04%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Precision Biosciences, and consider following DTIL for alerts when major investors trade the stock.